593 institutions hold shares in Horizon Therapeutics Public Limited Company (HZNP), with 2.53M shares held by insiders accounting for 1.13% while institutional investors hold 91.94% of the company’s shares. The shares outstanding are 220.63M, and float is at 217.89M with Short Float at 3.00%. Institutions hold 90.90% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 19.92 million shares valued at $1.46 billion. The investor’s holdings represent 8.89% of the HZNP Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 14.21 million shares valued at $1.04 billion to account for 6.34% of the shares outstanding. The other top investors are FMR, LLC which holds 13.25 million shares representing 5.92% and valued at over $969.49 million, while Avoro Capital Advisors LLC holds 4.02% of the shares totaling 9.0 million with a market value of $658.35 million.
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) is 24.42% higher on its value in year-to-date trading and has touched a low of $23.81 and a high of $96.54 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The HZNP stock was last observed hovering at around $94.49 in the last trading session, with the day’s loss setting it -3.48% off its average median price target of $118.00 for the next 12 months. It is also 27.19% off the consensus price target high of $125.00 offered by 9 analysts, but current levels are -3.42% lower than the price target low of $88.00 for the same period.
Currently trading at $91.01, the stock is 3.19% and 13.84% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.73 million and changing -3.68% at the moment leaves the stock 29.53% off its SMA200. HZNP registered 164.64% gain for a year compared to 6-month gain of 21.15%. The firm has a 50-day simple moving average (SMA 50) of $83.74 and a 200-day simple moving average (SMA200) of $76.96.
The stock witnessed a 18.13% loss in the last 1 month and extending the period to 3 months gives it a 29.22%, and is -4.68% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.61% over the week and 4.69% over the month.
Horizon Therapeutics Public Limited Company (HZNP) has around 1395 employees, a market worth around $20.31B and $2.20B in sales. Current P/E ratio is 55.77 and Fwd P/E is 17.40. Profit margin for the company is 17.70%. Distance from 52-week low is 282.23% and -5.73% from its 52-week high. The company has generated returns on investments over the last 12 months (8.90%).
Horizon Therapeutics Public Limited Company (HZNP) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Horizon Therapeutics Public Limited Company (HZNP) is a “Buy”. 9 analysts offering their recommendations for the stock have an average rating of 1.70, where 1 rate it as a Hold and 0 think it is a “Overweight”. 8 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Horizon Therapeutics Public Limited Company is expected to release its quarterly report on 05/12/2021 and quarterly earnings per share for the current quarter are estimated at $0.27 with sales reaching $414.37M over the same period.The EPS is expected to shrink by -37.60% this year, but quarterly earnings will post 26.70% year-over-year. Quarterly sales are estimated to grow 16.40% in year-over-year returns.
Horizon Therapeutics Public Limited Company (HZNP) Insider Activity
A total of 144 insider transactions have happened at Horizon Therapeutics Public Limited Company (HZNP) in the last six months, with sales accounting for 82 and purchases happening 62 times. The most recent transaction is an insider sale by Shannon James Samuel, the company’s Director. SEC filings show that Shannon James Samuel sold 7,232 shares of the company’s common stock on Mar 01 at a price of $91.30 per share for a total of $0.66 million. Following the sale, the insider now owns 0.0 shares.
Horizon Therapeutics Public Limited Company disclosed in a document filed with the SEC on Mar 01 that Walbert Timothy P (Chairman, President and CEO) sold a total of 26,975 shares of the company’s common stock. The trade occurred on Mar 01 and was made at $91.35 per share for $2.46 million. Following the transaction, the insider now directly holds 0.92 million shares of the HZNP stock.
Still, SEC filings show that on Mar 01, SANTINI GINO (Director) disposed off 12,000 shares at an average price of $91.47 for $1.1 million. The insider now directly holds 23,795 shares of Horizon Therapeutics Public Limited Company (HZNP).
Horizon Therapeutics Public Limited Company (HZNP): Who are the competitors?
The company’s main competitors (and peers) include AstraZeneca PLC (AZN) that is trading 3.60% up over the past 12 months. Pfizer Inc. (PFE) is 5.80% up on the 1-year trading charts. Short interest in the company’s stock has risen 9.02% from the last report on Jan 14, 2021 to stand at a total of 5.95 million short shares sold with a short interest ratio of 3.04.